Shanghai Shenqi Pharmaceutical Investment Management Co (600613) Fair Value & Analysis
Healthcare · CN · Market cap 2.7B CNY
Fair value as of: Aug 9, 2026
From 26 valuation models · updated 2 days ago
Share price +9.7% over the past month.
A solid business, but screening 48% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥2.71). The favourable scenario is already priced in.
- Solid but not exceptional quality (63/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥1.32 to ¥2.71) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 9, 2026.
How to read this chart
60‑month range ¥4.17 – ¥13.78 · fair‑value band ¥1.32 – ¥2.71 · the ¥5.19 price screens above the ¥2.71 fair value. Dashed = 300-day average. As of Aug 9, 2026.
Analysis
Shanghai Shenqi Pharmaceutical Investment Management Co (600613) currently trades at ¥5.19, while our model-based Fair Value estimate is ¥2.71, implying the stock looks roughly 47.8% overvalued today. The Quality Score stands at 63/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Shanghai Shenqi Pharmaceutical Investment Management Co generated revenue of 1.9B CNY at a net margin of 1.9%. Revenue declined 11.9% year over year. It earns a return on equity of 1.5%. The balance sheet holds a net cash position of 612M CNY. Fundamentals as of Aug 9, 2026
Our scenario range runs from ¥1.32 (bear case) to ¥2.71 (bull case); at ¥5.19, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high and 9% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -48%, 600613 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥4.96) versus Earnings-Based (¥1.05). Highest evidence: Growth DCF (80).
Notify me when 600613 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 9, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 63 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China.
Full company description
Shanghai Shenqi Pharmaceutical Investment Management Co., Ltd., together with its subsidiaries, operates as a pharmaceutical manufacturing holding investment company in China. The company engages in the research and development, and production of anti-tumor, cardiovascular, cerebrovascular, rheumatism bone pain, tonic and sedative, cold and cough, anti-fungal, gynecology, and other treatment fields. Its products include prescription drugs and OTC products, including products include sodium cantharidate vitamin B6 injection, sodium cantharidin injection, loquat cough granules, strong loquat dew, loquat cough capsules, jinwu gutong capsules, coral ringworm net, jingwu capsules, quantianma capsules, yindan xintai pills, etc. The company was founded in 1990 and is based in Shanghai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Shenqi Pharmaceutical Investment Management Co reported revenue of ¥2.0B in FY2025 versus ¥2.3B in FY2021, a compound −4.0%/yr. Reported net income was ¥38.2M in FY2025, compounding −13.9%/yr from FY2021.
of which total revenue +6.6 pp · buybacks/dilution −0.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
600613 screens 48% overvalued. Compare with Eli Lilly and Company →
Peer Group
Drug Manufacturers - General · 76 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 9, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,182 | $396.77 | -66% |
| Johnson & Johnson, JNJ | $257.59 | $169.04 | -34% |
| AbbVie Inc ABBV | $254.49 | $67.72 | -73% |
| Roche Holding 1RO | €392.80 | €226.68 | -42% |
| Merck & Co MRK | €108.08 | €121.54 | +12% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| AstraZeneca PLC AZN | $171.61 | $129.54 | -25% |
| Novo Nordisk A/S NOVOB | kr 329.90 | kr 409.46 | +24% |
| Amgen Inc AMGN | $363.39 | $252.02 | -31% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
Compare Shanghai Shenqi Pharmaceutical Investment Management Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Shenqi Pharmaceutical Investment Management Co (600613) overvalued or undervalued?
What is the fair value of 600613?
What is the quality score of 600613?
What is the revenue of Shanghai Shenqi Pharmaceutical Investment Management Co (600613)?
What is the net profit margin of 600613?
Does Shanghai Shenqi Pharmaceutical Investment Management Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Shanghai Shenqi Pharmaceutical Investment Management Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.